OSE Immunotherapeutics Reports Cash Position and Business Update
News related to:OSE Immunotherapeutics · 2 min read
OSE Immunotherapeutics, a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, reported its cash position as of June 30, 2026, and provided an update on its business.
As of June 30, 2026, OSE Immunotherapeutics had a cash position of €11.1 million, down from €17.0 million as of March 31, 2026. The company confirmed its cash runway through December 2026, based on a flexible bridge equity financing implemented in May 2026. This financing, in addition to available cash, is estimated to be sufficient to fund operations until the end of the year. The cash runway does not include any potential future milestone payments from existing partnerships.
The company is actively engaging with institutional investors in the United States and Europe to extend its cash runway beyond key upcoming value inflection points. In this context, the publication of the first half 2026 financial results has been postponed.
Enrollment in the international pivotal Phase 3 clinical trial ARTEMIA, evaluating Tedopi® in second-line non-small cell lung cancer (NSCLC), is on track for completion by the end of December 2026. The interim futility analysis for ARTEMIA, originally anticipated in Q3 2026, is now expected in early 2027 due to a lower number of death events than initially expected.
In other clinical trials, OSE Immunotherapeutics reported positive topline results from the TEDOVA/GINECO-OV244b/ENGOT-ov58 academic, international, Phase 2 trial, which evaluated Tedopi® with or without pembrolizumab as a maintenance treatment in 185 patients with platinum-sensitive recurrent ovarian cancer (PSOC). The primary endpoint was progression-free survival (PFS), and the results showed a statistically significant improvement in PFS for the combination of Tedopi® and pembrolizumab compared to best supportive care (median PFS: 4.1 months vs 2.8 months; HR=0.53; p<0.001). The addition of pembrolizumab to Tedopi® resulted in a 28% reduction in the risk of progression or death (HR=0.72, p=0.074). These results were presented by principal investigator Alexandra Leary, MD, PhD, at the ASCO 2026 Annual Meeting in May 2026.
Topline results from the Combi-TED Phase 2 international clinical trial, sponsored by FoRT and evaluating Tedopi® in second-line treatment in combination with anti-PD1 or chemotherapy in 105 patients with metastatic NSCLC, will be presented by principal investigator Federico Cappuzzo, MD, PhD, at the ESMO 2026 Annual Meeting on October 25, 2026, in Madrid, Spain.
The subcutaneous formulation of lusvertikimab (IL-7R) is on track for validation by mid-2027. The achieved concentration at 225mg per mL, based on previously evaluated intravenous efficacious doses in Phase 2 of 450mg and 850mg, is potentially compatible with the use of an autoinjector device. The application for authorization of a Phase I study in healthy volunteers is currently being prepared, with results expected by mid-2027.
OSE Immunotherapeutics continues to evaluate several complementary options, including a potential new strategic partnership involving one of its proprietary assets, restructuring of its existing debt, and potential milestone payments from current partnerships.